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Abstract
Background: Therapeutic hypothermia reduces death and disability after moderate or severe neonatal
encephalopathy in high-income countries and is used as standard therapy in these settings. However, the safety
and efficacy of cooling therapy in low- and middle-income countries (LMICs), where 99% of the disease burden
occurs, remains unclear. We will examine whether whole body cooling reduces death or neurodisability at 18–22
months after neonatal encephalopathy, in LMICs.
Methods: We will randomly allocate 408 term or near-term babies (aged≤ 6 h) with moderate or severe neonatal
encephalopathy admitted to public sector neonatal units in LMIC countries (India, Bangladesh or Sri Lanka), to either
usual care alone or whole-body cooling with usual care. Babies allocated to the cooling arm will have core body
temperature maintained at 33.5 °C using a servo-controlled cooling device for 72 h, followed by re-warming at 0.5 °C
per hour. All babies will have detailed infection screening at the time of recruitment and 3 Telsa cerebral magnetic
resonance imaging and spectroscopy at 1–2 weeks after birth. Our primary endpoint is death or moderate or severe
disability at the age of 18 months.
Discussion: Upon completion, HELIX will be the largest cooling trial in neonatal encephalopathy and will provide a
definitive answer regarding the safety and efficacy of cooling therapy for neonatal encephalopathy in LMICs. The trial
will also provide important data about the influence of co-existent perinatal infection on the efficacy of hypothermic
neuroprotection.
Trial registration: ClinicalTrials.gov, NCT02387385. Registered on 27 February 2015.
Background
Every year, approximately one million babies die in low-
and middle-income countries (LMIC) due to neonatal
encephalopathy – a condition arising from an unexpected
lack of cerebral blood flow and oxygen supply to the fetal
brain at the time of birth [1]. Approximately one-third of
infants with moderate or severe encephalopathy will die
during the newborn period and up to three-quarters of
survivors will develop long-term neurodisability [2, 3].
Until recently, there was no effective treatment for
this condition and the management was limited to
supportive care.
Several high-quality cooling trials have been conducted
in high-income countries in the past decade [4–6]. The
meta-analyses of these trials have convincingly demon-
strated that selective head or whole-body cooling, along
with optimal tertiary intensive care, reduces mortality
(risk ratio [RR] 0.8; 95% confidence interval [CI] 0.7–0.9;
p = 0.005) and improves survival with normal
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neurological outcome (RR 1.5; 95% CI 1.2–1.9; p < 0.001)
after neonatal encephalopathy in these settings [7, 8].
The protective effect of cooling persists into later child-
hood [9, 10]. Whole-body cooling is now widely used as
a standard therapy for encephalopathy in the UK and
other high-income countries [11].
The safety and efficacy data on cooling therapy from
high-income cooling trials cannot be extrapolated to
LMICs, due to differences in population co-morbidities,
particularly co-existent perinatal infection, growth
restriction and meconium aspiration syndrome, and lack
advanced cardio-respiratory intensive care facilities [12].
Preclinical data suggest that the brain injury is worse
and the neuroprotective effect of hypothermia in
neonatal encephalopathy is lost in the presence of
co-existent infection, particularly with gram-negative
organisms [13].
We systematically reviewed the published literature on
the safety and efficacy of cooling therapy for neonatal en-
cephalopathy due to hypoxia-ischemia in LMICs [14]. All
published studies were small and/or of poor quality. Two
studies reported increased mortality with cooling [15, 16].
A meta-analysis of all these trials showed a trend towards
reduced mortality; however, this was not statistically sig-
nificant (RR 0.74; 95% CI 0.4–1.3). More importantly, the
CIs were wide and therefore significant benefits or harm
could not be excluded. There were no data on long-term
neurological follow-up after cooling therapy [14]. Thus,
before cooling therapy is widely used as standard care
therapy in LMICs, safety and efficacy data from ad-
equately powered clinical trials are required.
Aims
Primary
To examine whether whole-body cooling to 33.5 °C, ini-
tiated within 6 h of birth and continued for 72 h, re-
duces death or moderate or severe neurodisability at
18–22 months after neonatal encephalopathy, in LMICs.
Secondary
 To examine if whole-body cooling reduces mortality
at hospital discharge and at 18–22 months after neo-
natal encephalopathy
 To examine if whole-body cooling reduces moderate
or severe neurodisability at 18–22 months in survi-
vors after neonatal encephalopathy
 To examine if whole-body cooling reduces brain in-
jury on magnetic resonance imaging (MRI) and spec-
troscopy performed during the neonatal period
Methods
This is a multi-country two arm unblinded pragmatic
randomised controlled trial of whole-body cooling along
with usual supportive care vs. usual care alone. We plan
to recruit 408 babies with moderate or severe neonatal
encephalopathy from public sector neonatal units in
LMICs over a three-year period. We anticipate approxi-
mately 1200 babies will be screened for eligibility to
achieve the required target.
The treatment duration (cooling therapy) is 72 h;
however, the temperature of all recruited babies will be
monitored during the first week after birth. Any
temperature rise > 37.5 °C will be actively treated, both
in the cooling and usual care arms, as fever increases
brain injury and adverse outcomes after neonatal
encephalopathy. The neurological outcomes will be
assessed at 18–22 months of age. The trial duration will
be five years, consisting of a staggered start-up period,
36 months of recruitment followed by a further
18 months of follow-up, and a final five months for data
analysis and write-up.
Before the start of recruitment, the local clinical staff
at the recruiting centres will have an intensive training
on all aspects of the trial and research governance. All
staff involved in the study will be required to maintain
an up-to-date ICH-GCP certification.
Inclusion criteria
To ensure wider applicability of the trial intervention,
we will use exclusive clinical criteria for selection of at
risk infants. Although blood gas analysis and amplitude
integrated electroencephalogram may be performed as a
part of the clinical care, they will not form part of the
eligibility criteria, as these investigations are not widely
available in LMICs. Furthermore, accurate Apgar scores
are often not available when babies are born at home or
in other hospitals and then transferred to the recruiting
centres, and often not collected beyond 5 min after
birth. Hence, the inclusion criteria from the high-
income country cooling trials are inappropriate for
LMICs.
Therefore, our inclusion criteria are primarily based
on a structured neurological examination using modified
Sarnat staging.
Our preliminary data have shown that the HELIX in-
clusion criteria will identify most infants at high risk of
adverse outcomes, without including infants with milder
encephalopathy. To be eligible for recruitment, all three
criteria below must be met:
1. age ≤ 6 h, birthweight ≥ 1.8 kg, gestation ≥ 36 weeks
(based on reported last menstrual period or
ultrasound);
2. need for continued resuscitation at 5 min of age
and/or 5-min Apgar score < 6 (for babies born at
hospital) or lack of crying by 5 min of age (for babies
born at home);
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3. Evidence of moderate or severe encephalopathy at <
6 h of age on a structured clinical examination based
on modified Sarnat staging (Table 1).
Exclusion criteria
 Absent heart rate at 10 min of age despite adequate
resuscitation or imminent death
 Major life-threatening congenital malformations
 Migrant family or parents unable/unlikely to come
back for follow-up at 18 months (expected to be less
than 5% of eligible population)
Outcome measures
Primary outcome measure
Severe disability was defined as any of the following:
a Bayley III [17] cognitive score < 70; a Gross Motor
Function Classification System (GMFCS) level of 3–5
[18]; blindness; or profound hearing loss (inability to
understand commands despite amplification).
Moderate disability was defined as a Bayley III cogni-
tive score of 70–84 and either a GMFCS level of 2,
seizure disorder or a hearing deficit requiring amplifica-
tion to understand commands.
Secondary outcome measures
Clinical outcomes (before discharge from hospital)
 Mortality from any cause before discharge from
hospital
 Major intracranial haemorrhage on cranial
ultrasound
 Gastric bleeds (fresh blood > 5 mL from nasogastric tube)
 Persistent hypotension (mean blood pressure <
25 mmHg despite maximum inotropic support)
 Pulmonary haemorrhage (copious bloody secretions
with clinical deterioration requiring change(s) in
ventilatory management)
 Persistent pulmonary hypertension (severe
hypoxemia disproportionate to the severity of lung
disease with a significant pre- and post-ductal
saturation difference on pulse oximetry)
 Prolonged blood coagulation requiring blood
products
Table 1 Modified Sarnat scale for clinical encephalopathy staging
Categories (total 6) Signs of neonatal encephalopathy (NE) in each category
Normal Mild NE Moderate NE Severe NE
1. Level of consciousness
Alert, responsive to external stimuli
(state dependent, e.g. post feeds)
Hyper-alert, has a stare, jitteriness,
high-pitched cry, exaggerated
responds to minimal stimuli,
inconsolable
Lethargic Stupor/coma
2. Spontaneous activity
Changes position when awake Normal or decreased Decreased activity No activity
3. Posture
Predominantly flexed when quiet Mild flexion of distal joints (fingers,
wrist usually)
Moderate flexion of distal joint,
complete extension
Decerebrate
4. Tone
Strong flexor tone in all
extremities + strong flexor hip tone
Normal or slightly increased
peripheral tone
Hypotonia (focal or general)
or hypertonia
Flaccid
Rigid
5. Primitive reflexes (circle only the highest level in each sign; the maximum score is only 1 in any one category)
Suck Strong, easily illicit Weak, poor Weak but has a bite Absent
Moro Complete Partial response, low threshold
to illicit
Incomplete Absent
6. Autonomic system (circle only the highest level in each sign; the maximum score is only 1 in any one category)
Pupils In dark: 2.5–4.5 mm; in
light: 1.5–2.5 mm
Mydriasis Constricted Deviation/dilated/non-
reactive to light
Heart rate 100–160 bpm Tachycardia (HR > 160) Bradycardia (HR < 100) Variable HR
Respiration Regular respirations Hyperventilation (RR > 60/min) Periodic breathing Apnoea or requires
ventilator
Total score
The level of encephalopathy will be assigned based on which level of signs (moderate or severe) predominates among the six categories. If moderate and severe
signs are equally distributed, the designation is then based on the highest level in Category #1: The level of consciousness. If the level of consciousness is equal,
then designation of the NE stage is based on the tone (Category #4). An infant who has seizures will be moderate or severe NE, depending on the neurologic
exam. Seizure with normal or mild NE or moderate NE on neurologic exam will be ‘Moderate NE’. Seizure with severe NE will be ‘Severe NE’
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 Culture-proven early onset sepsis (isolation/
identification of a pathogenic organism from blood
and/or cerebrospinal fluid along with clinical
evidence of sepsis and elevation of C-reactive
protein)
 Necrotising enterocolitis (abdominal distension,
increased gastric aspirates and/or blood in stools,
together with abdominal X-ray showing bowel
oedema, pneumatosis or pneumoperitoneum, i.e.
Bell’s staging 2 or 3)
 Cardiac arrhythmia requiring therapy
 Severe thrombocytopenia (<25,000)
 Persistent metabolic acidosis lasting over 12 h after
birth
 Renal failure (anuria > 48 h with azotaemia)
 Pneumonia (infiltrates on chest X-ray consistent
with infection or aspiration)
 Subcutaneous fat necrosis
 Neurological examination at discharge
 Duration of hospitalisation
Neonatal cerebral magnetic resonance biomarkers
 Brain injury score on conventional MRI [19, 20]
 Proton magnetic resonance spectroscopy thalamic
lactate/N-acetylaspartate peak area ratio and
absolute concentration of N-acetylaspartate [21]
 Whole brain maps of diffusion tensor indices [22]
Neurodisability (18–22 months)
 Mortality
 Severe neurodevelopmental disability (severe
disability was defined as any of the following: a
Bayley III [17] cognitive score of < 70; a GMFCS
level of 3–5 [18]; blindness; or profound hearing loss
(inability to understand commands despite
amplification)
 Microcephaly (head circumference more than 2
standard deviations below the mean)
Screening and neurological examination
All infants admitted to the neonatal unit with perinatal
asphyxia will be screened for eligibility. Out-born babies
meeting the inclusion criteria will be eligible for recruit-
ment, irrespective of the temperature at admission to
the neonatal unit (Additional file 1). Potentially eligible
cases will have a detailed neurological examination by a
designated neonatal doctor who is trained and accre-
dited in NICHD neurological examination modified
from the Sarnat staging (Table 1) [5]. Briefly, this scoring
system assesses six categories of neurological symptoms.
The highest score in each category will be recorded. The
level of encephalopathy is determined based on the pre-
dominant degree of neurological abnormality (moderate
or severe) across the six categories. Three out of the
total six categories must be moderate or severe for the
baby to be eligible.
Infants who have seizures will be considered to have
moderate or severe neonatal encephalopathy depending
on the neurological examination. Seizures combined
with otherwise mild or moderate encephalopathy on
neurological examination will be considered as moderate
encephalopathy. Seizures combined with severe enceph-
alopathy will be considered as severe encephalopathy.
Sedatives or analgesics given before the neurological
examination will be recorded in the case report
form (CRF).
Treatment assignment and randomisation
As soon as informed parental consent is obtained for an
eligible infant, the recruiting clinician will obtain the
treatment assignment, which will be either ‘usual care
with cooling’ or ‘usual care only’, using an Internet-based
randomisation system (Sealed Envelope; https://
www.sealedenvelope.com). Minimisation will be used to
ensure balance between the groups with respect to the
severity of encephalopathy at each centre. Further details
are given in the statistical analysis plan.
Researchers will not be blinded to the intervention
(cooling therapy). However, the neurological outcome
evaluation at 18 months will be undertaken by assessors
masked to the treatment allocation.
Cooling therapy
Therapeutic hypothermia will be administered using a
servo-controlled whole-body cooling device, that has
an effective cooling time (percentage of time for
which the core body temperature is maintained within
the target range of 33 °C to 34 °C) of over 90% [23].
Briefly, this would consist of attaching the mattress to
the servo-controlled device, refilling coolant, keeping
the baby on the mattress, placing a rectal probe,
switching the machine on and selecting the appropri-
ate program. Babies are kept on a radiant warmer
with heating turned off and are not clothed, except
for nappies. The cooling device will maintain the rec-
tal temperature of the baby within 33 °C to 34 °C
and will alarm when temperatures are out of this
range (e.g. after displacement of the rectal probe).
The clinical team will record rectal temperature
hourly in the data collection form. In addition, the
temperature data will be downloaded from the cool-
ing device and compared with the manual records to
ensure data entry accuracy. After 72 h of cooling, the
baby will be automatically re-warmed at 0.5 °C per
hour by the cooling device. Following re-warming all
babies will have continuous rectal temperature moni-
toring until 90 h of age, and then every 8 h for the
first week after birth.
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Babies with a low temperature (rectal temperature < 35.5 °C)
on admission to the neonatal unit
It is possible that rapid rewarming (>0.5 °C per hour)
may result in increased brain injury and seizures. If these
babies are already randomised to usual care and then
kept under a servo-controlled radiant warmer set at
36.5 °C, rapid re-warming may occur in less than 1 h,
thus worsening the outcome.
Hence, any baby admitted with a low rectal
temperature (<35.5 °C) who is recruited to the usual care
arm will be slowly rewarmed, at a rate not more than
0.5 °C per hour using the protocol below:
1. set the radiant warmer temperature 0.5 °C higher
than the baby’s rectal temperature and increase this
by 0.5 °C every hour, until the rectal temperature
reaches 36.5 °C;
2. if the radiant warmer servo-controlled mode fails,
use manual mode keeping the heating output low
(e.g. 20%), so that the baby’s rectal temperature does
not rise by more than 0.5 °C per hour;
3. if no radiant warmer available, keep the baby
covered in warm clothes, so that the temperature
slowly increases to 36.5 °C over several hours. This
may take as long as 6–12 h.
Babies with a core temperature of > 37.5 °C during the first
week after birth
All the major neonatal cooling trials to date had up to
one-quarter of infants in the usual care having core tem-
peratures > 37.5 °C. Subsequently, analysis of the trial
data suggests that core temperatures above 37.5 °C ad-
versely affect brain injury and worsen their outcome
[24]. Therefore, any potential benefit seen with cooling
may be spuriously related to the overheating of usual
care babies. Moreover, a recent trial in adults have
shown that ‘therapeutic normothermia’ is as effective as
‘therapeutic hypothermia’ following cardiac arrest [25].
Hence, we will use a more aggressive approach for
preventing and treating elevated core temperatures in
the usual care arm than the previous neonatal cooling
trials. Fever may occur at any time in babies in the
usual care arm and sometimes during the post-
rewarming phase in the cooling arm. Babies allocated
to usual care will be nursed on servo-control radiant
warmer with a set temperature of 35.5 °C to 36 °C,
to prevent any accidental overheating. Any rise in
temperature > 37.5 °C, will be aggressively treated by
turning off any radiant heater or warmer if in use,
using fans, tepid sponging, antipyretics and, if neces-
sary, using the servo-controlled cooling device in a
‘normothermia mode’. In addition, any infective cause
for fever will be investigated and treated, including
lumbar puncture if appropriate.
Criteria for stopping cooling therapy
 Refractory hypotension (mean blood pressure <
25 mmHg) despite optimal inotropic and volume
support
 Life-threatening/massive haemorrhage
 Parent or clinician request to stop cooling therapy,
for example if the baby requires any surgical
procedure during first three days
Supportive care and monitoring
The general management of babies will be standardised
at the participating centres and will not permit therapies
like steroids, mannitol or other experimental therapies
in recruited infants.
Hourly vital signs (oxygen saturation, heart rate, non-
invasive blood pressure, rectal temperature) will be re-
corded in the HELIX CRF in all infants. Additional mon-
itoring will be dictated by the clinical condition and
local guidelines.
Infants may also receive intravenous fluids, antibiotics,
ventilatory support, inotropes, blood products, sedation,
muscle relaxants and anti-convulsants as per the local
clinical practice. The babies undergoing cooling therapy
will also receive sedation, if they are ventilated or if there
is any evidence of stress (for example, shivering, unex-
plained tachycardia).
Detailed neurological examination (using NICHD cri-
teria) will be performed within 6 h of birth, then at day
3 and at discharge from hospital.
Baseline assessments and data collection
The following data points will be recorded in the CRF:
1. maternal (antenatal) and delivery details including
resuscitation details;
2. time and date of birth, time of randomisation and
start of cooling;
3. birthweight, gestation, gender and head circumference;
4. hourly rectal temperature profile in all infants for
the first 90 h;
5. neurological examination within 6 h, at day 3 and at
the time of discharge;
6. full blood count (including platelets, CRP and
differential white cell count) within 6 h of birth and
between days 4 and 7, as a part of clinical care;
7. Blood culture within 6 h of birth and between days
4 and 7;
8. biochemical series (including blood gas, sugar, urea,
creatinine, electrolytes and coagulation profile) as a
part of clinical care;
9. cranial ultrasound examination (within 72 h) to
examine for major intracranial bleeds as a part of
clinical care.
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Each anonymised CRF will be scanned and emailed to
the HELIX trial manager at Imperial College London for
quality checks within 48 h of completion. The signed off
CRFs will be entered into the HELIX trial database
(Redcap®).
Screening for perinatal infection
Preclinical evidence suggests that co-existent bacterial
infections, particularly those due to gram-negative
bacteria, may negate the neuroprotective effects of
hypothermia. Therefore, we will perform advanced mo-
lecular, histological and transcriptomic evaluation in
addition to standard automated blood cultures (Bactec),
to identify any co-existent perinatal infection (Fig. 1).
Whenever possible, bloods will be collected before
giving antibiotics. Babies who had antibiotics before the
blood collection (for example, babies referred from other
hospitals) will be noted separately.
This will include:
 blood for targeted polymerase chain reaction (qPCR)
to transcriptomic signatures to detect common
bacterial pathogens within 6 h of birth;
 a small section of the umbilical cord (fetal end) for
histopathological examination for funisitis. In
addition, a section from the placenta will be
collected whenever feasible. An experienced
perinatal pathologist will report histopathology,
masked to the clinical data.
We will use multiplex real time PCR (qPCR) on blood
to identify babies with neonatal sepsis, using a panel of
primers for both specific detection of common patho-
gens and generic detection. This will include Enterobac-
teriacae, Fusobacteria spps., Staphylococcus aureus,
coagulase-negative Staphylococci, and Streptococcus spps
including Group A and B Streptococcus, Pneumococcus
and Peptostreptococcus spps), qPCR for quantitation of
total 16 s rDNA [26]. Our preliminary data suggest the
vast majority of pathogens are gram-negative, and unlike
in high-income countries, group B streptococci is
extremely rare in these settings.
Following RNA extraction from the whole blood
collected in an RNA stabilising solution, we will perform
next generation sequencing (paired end) and alignment.
The sequenced data will be examined for the established
signatures of bacterial infections recently reported from
Imperial College London [27].
Magnetic resonance imaging and spectroscopy
The treatment effect of cooling therapy on brain injury
will be assessed and quantified using MRI and spectros-
copy. All recruited infants (surviving beyond 1 week)
will have an MR scan at 7–14 days of age. Preparation of
the baby for MRI is given in Additional file 2.
All MR scans will be performed on 3 T scanners
(Philips, Siemens or GE) using common harmonised se-
quences developed as a part of the Magnetic Resonance
Biomarkers in Neonatal Encephalopathy (MARBLE)
study [28]. 3 T MR scanning offers considerable benefits
for MR spectroscopy, over 1.5 T imaging.
MR scanners will be calibrated using adult volunteer
brain scans using the same sequences.
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT** -t1 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 7-14 Hospital 
discharge
3 m 6 m 12 m 18m to 22 m
ENROLMENT
Antenatal history X
Birth history X
Postnatal history X
Neurological examination X
Eligibility screen X
Video recording of the 
consenting process X
Written informed consent X
Randomisation X
INTERVENTION (Age < 6 hours at start of intervention)
Whole body cooling
Usual care X X X
ASSESSMENTS
Rectal temperature (1h) X X X X X X
Blood gas analysis X X X X
Full blood count X X
Renal and liver function X
Coagulation screen X
Infection screen X X
qPCR X
Transcriptomics X
Cranial ultrasound X
Neurological examination X X X X X
MRI and MR spectroscopy X
Telephone follow-up X X X
Neurodevelopmental 
assessment X
NB: m=month; qPCR= quantitative polymerise chain reaction; MRI = magnetic resonance imaging
Fig. 1 Schedule of enrolment, intervention, and assessments
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Conventional MRI protocol
 T1-weighted – 3D MPRAGE (1-mm isotropic
resolution);
 T2-weighted – 2D axial TSE (0.5-mm in-plane
resolution, 3-mm slices);
 Diffusion – 2D axial SE-EPI (2-mm isotropic
resolution, b = 0.750 s mm-2).
MR spectroscopy protocol
 Surveys pre- and post-spectroscopy for detection of
gross motion;
 PRESS (15 × 15 × 15 mm3, water suppressed, echo
time = 288 ms) for metabolite peak area ratios;
 STEAM (15 × 15 × 15 mm3, water suppressed, dual
repetition time, echo time = 20 ms) for relaxation
corrected metabolite signals;
 STEAM (15 × 15 × 15 mm3, water unsuppressed,
fixed repetition time, multiple echo times) for
internal water referencing to provide metabolite
concentrations.
The anonymised MR data will be encrypted and trans-
ferred to the Centre for Perinatal Neuroscience by Im-
perial College London file transfer protocols for analysis
and storage. All MR data will be analysed centrally,
masked to the allocation or other outcomes. Details of
MR sequences are given in Additional file 3.
The raw spectroscopy data will be post-processed
using software developed in-house at Imperial College
London (Python v2.7) and an in-house implementation
of TARQUIN will be used to calculate metabolite con-
centrations from the STEAM spectra. LCModel will be
used to calculate metabolite peak area ratios from the
PRESS spectra.
Diffusion imaging data will be processed using the
FMRIB Software Library (FSL, v5.0) and registered
across individuals using DTI-TK (http://dti-tk.sourcefor-
ge.net/pmwiki/pmwiki.php). The resulting maps of
diffusion tensor indices will be compared between
participants using FSL. Postnatal age and postmenstrual
age at scan will be introduced as confounding variables
into the general linear model rendering results age-
independent.
MR biomarker endpoints
 thalamic N-acetylaspartate concentration deter-
mined from STEAM spectroscopy;
 thalamic lactate/N-acetylaspartate metabolite peak
area ratio determined from PRESS spectroscopy;
 white matter fractional anisotropy determined from
diffusion imaging using tract based spatial statistics;
 brain injury severity score determined from
conventional MRI [20].
Follow-up and neurological assessments
The recruiting centres will maintain regular (3–6
months) telephone contact with parents to minimise
attrition. The following information will be recorded at
each contact:
1. general health status of the baby;
2. any change in home address or telephone number.
Each recruiting centre will have a dedicated and expe-
rienced neurodevelopmental paediatrician trained in
Bayley Scales of Infant Development (Version III), who
will assess the babies aged 18–22 months, masked to the
allocation. Inter-observer variability will be addressed
and corrected before the start of assessments, by
comparing against a gold standard examiner (RS;
Pearson’s trainer for Bayley Scales of Infant Develop-
ment (Version III). The Bayley scales will be adminis-
tered in one of the local languages (mother tongue of
the child) – Hindi, Marathi, Kannada, Tamil, Malayalam,
Singhalese, Telugu or Bangla.
Detailed medical history, neurological examination
and Gross Motor Function Classification System assess-
ment will be also obtained during this visit using a pre-
defined proforma and then entered into the HELIX trial
database.
Severe disability will be defined as any one of the fol-
lowing: Bayley III cognitive composite score < 70; Gross
Motor Function Classification System level 3–5; hearing
impairment requiring hearing aids/cochlear implant; or
blindness.
Moderate disability will be defined as cognitive com-
posite score 70–84 and one or more of the following:
Gross Motor Function Classification System level II;
hearing impairment with no amplification/cochlear im-
plant; or a persistent seizure disorder.
The examiner will feed back the results of the neuro-
developmental outcome tests to the parents, immedi-
ately after the assessment. A copy of this report will be
provided to the local principal investigator for clinical
management. We will also collect information of various
morbidities and medical support required during infancy
and obtain detailed anthropometry to assess the nutri-
tional status during the 18-month follow-up visit.
Adverse events
All known adverse events relating to neonatal encephal-
opathy and cooling therapy are described in the parent
information leaflet and will be part of obtaining the in-
formed research consent, before the start of cooling
therapy.
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The following clinical events (1–9) occur due to the
underlying disease (neonatal encephalopathy). Cooling
trials from high-income countries have shown that
cooling therapy reduces/does not increase the incidence
of many of these clinical events in encephalopathic
babies.
1. Death during neonatal period or during infancy
2. Brain injury observed with MRI
3. Adverse neurodevelopmental outcome at 18 months
and at childhood
4. Persistent pulmonary hypertension
5. Metabolic imbalances
6. Cardiac arrhythmia
7. Renal failure
8. Coagulopathy
9. Gastric bleeds
Cooling therapy may increase the risk of the following
adverse events noted in the previous randomised con-
trolled trials.
1. Thrombocytopenia and increased need for platelet
transfusions
2. Subcutaneous fat necrosis
All adverse events are expected to occur within the
cooling period (first 72 h) or within 72 h of re-warming.
Adverse reactions occurring subsequently (after one
week of life), except subcutaneous fat necrosis, will not
be considered as intervention related. Subcutaneous fat
necrosis may occur several weeks after the therapy.
If an unexpected serious adverse event (SAE) occurs
(i.e. an event not mentioned in the above list), it should
be reported to the HELIX trial manager within 24 h,
using one of the SAE report forms. The HELIX trial
manager will ensure that the independent data monitor-
ing committee (IDMC) and the research ethics commit-
tee (REC) are informed accordingly.
Statistical methods
The primary analysis will be a comparison of the in-
fants assigned to usual care plus whole-body cooling
with those infants assigned to usual care at random-
isation (i.e. intention-to-treat analysis population),
regardless of deviation from the protocol or whether
they received the allocated intervention. Demographic
factors, clinical characteristics and outcomes will be
summarised with counts (percentages) for categorical
variables, means (standard deviation [SD]) for nor-
mally distributed continuous variables or medians
(interquartile [IQR] or entire range) for non-normally
continuous variables. Further details are given in the
statistical analysis plan.
In order to establish both the magnitude and direction
of the effects of whole-body cooling intervention, com-
parative statistical analysis will entail calculating the RR
plus 95% CI for the primary outcome. The chi-square
test will be used to determine statistical significance,
with a 5% significance level used.
Secondary outcomes will be evaluated using a 5%
level of statistical significance, with 95% CIs reported,
to take account of the number of outcomes analysed.
The Chi-square test or Fisher’s exact test will be used
to analyse categorical outcomes with RRs reported
with 95% CIs. The unpaired t-test will be used to
analyse normally distributed continuous outcomes,
with the mean difference (plus 95% CI) reported.
Non-normally distributed continuous outcomes will
be transformed to normality or alternatively analysed
using the Mann–Whitney test. If the latter approach
is used, the median difference (plus 95% CI) between
groups will be reported.
Logistic regression will be used to perform an adjusted
analysis for the primary outcome to investigate the im-
pact of stratification/known prognostic factors including
the stage of neonatal encephalopathy.
Analysis of secondary outcomes will be clearly
delineated from the primary analysis in any statistical re-
ports produced. Results will be reported according to
the CONSORT statement.
The sample size is based on being able to detect a clin-
ically significant 30% relative risk reduction in death or
moderate/severe disability from 50% in the usual care
arm to 35% in the intervention (cooled) arm. Using a
two-sided 5% significance level and an 80% power, 183
babies per arm are required. Assuming a loss to follow-
up rate of around 10%, this comparison requires 204
babies per group, 408 babies in total, to be recruited. In
case the adverse outcomes (death and moderate/severe
disability) are higher (~65%) in the usual care arm, then
this sample size would provide 94% power to detect a
30% relative risk reduction with cooling.
Each CRF (pdf) will be send to the HELIX trial man-
ager within 48 h of discharge/death and all data queries
will be resolved in real time by the HELIX research
nurse/data entry person. The CRF will be signed off for
completion and entered into the HELIX Redcap data-
base by a dedicated data entry person at Imperial
College London. The HELIX trial manager will then for-
ward the trial data to an independent statistician, after
masking the allocation (as X and Y) for analysis. The
trial statistician will analyse the data for IDMC meetings
as per a predefined proforma (masked as A and B), at
six-monthly intervals or after recruitment of every 50
cases whichever is earlier. The temperature data will be
reported to the IDMC as adherence to target
temperature, rather than actual temperatures to prevent
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unmasking of the IDMC members. The principal investi-
gators will not have access to the trial data before lock-
ing, nor will they have any role in the data analysis. The
trial CONSORT diagram is given in Fig. 2.
Trial organisation
Independent Data Monitoring Committee (IDMC)
An IDMC will review the study’s progress. The IDMC
will be independent of the trial organisers. The IDMC
will meet every six months or after recruitment of 50
babies, whichever is earlier.
Meetings of the committee will be arranged periodic-
ally, as considered appropriate by the Chair.
The IDMC will inform the Trial Steering Committee
(TSC) if in their view:
 there is proof beyond reasonable doubt that the data
indicate that any part of the protocol under
investigation is either clearly indicated or contra-
indicated, either for all infants or for a subgroup of
trial participants;
 it is evident that no clear outcome will be obtained;
 safety signal.
The primary endpoint will be assessed 18 months after
the intervention has been performed. Given the planned
period of recruitment, the primary endpoint will not be
able to be assessed until majority of patients have been
recruited. Thus, it will not be possible to stop the study
early based on the study outcomes.
The membership of IDMC is detailed below:
 Professor Abbot Laptook (Chair, Professor for
Neonatology, Brown University, USA)
 Professor Shabbar Jaffar (Faculty of Epidemiology
and Population Health, London School of Hygiene
and Tropical Medicine, London, UK)
 Professor Niranjan Thomas (Professor of
Neonatology, Christian Medical College, Vellore,
India)
 Dr Aung Soe (Consultant Neonatologist, Medway
Hospital NHS Trust, Kent, UK)
The HELIX trial statistician will provide the trial data
for IDMC meetings according to a pre-defined reporting
format agreed by the IDMC.
Trial Steering Committee
The TSC will provide overall supervision of the study of
the Sponsor. Its terms of reference are:
1. to monitor and supervise the progress of the HELIX
trial towards its interim and overall objectives;
2. to review at regular intervals relevant information
from other sources (e.g. related studies);
3. to consider the recommendations of the IDMC.
Fig. 2 CONSORT diagram
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Project Management Group
The Project Management Group will oversee all aspects
of the day-to-day running of the study and will consist
of the investigators and the HELIX trial staff, based at
the HELIX Co-ordinating Centre at Madras Medical
College, Chennai, India and the Centre for Perinatal
Neuroscience, Imperial College London. The Project
Management Group will hold a monthly teleconference
of all HELIX investigators for the entire duration of the
trial to discuss the data quality and recruitment.
All correspondence with the REC will be retained in
the Trial Master File/Investigator Site File. Annual re-
ports will be submitted to the REC in accordance with
Imperial College London requirements. It is the Chief
Investigator’s responsibility to produce the annual re-
ports as required. Each participating site in India will
have local research ethics and other regulatory approvals
as per the local regulations.
Consent
The clinical team at each centre will explain the study to
the parents, provide study information leaflets (in the
appropriate local language – Kannada, Hindi, Tamil,
Telugu, Marathi, Bengali, Singhalese or Malayalam) and
will seek written informed consent. The entire consent-
ing processes (including explanation of the study to
parents) will be video-recorded. The digital video re-
cordings will be securely stored at the local centre and
at Imperial College London. The attending physician will
regularly meet with parents during the intervention
period to ensure that they understand the study proce-
dures, throughout the course of hospital stay.
Each participant’s right to refuse or withdraw from
the study without giving reasons will be respected at
all times. A withdrawal form will be filled in and
authorisation will be obtained for use of the previ-
ously collected data.
The site principal investigator will retain the ori-
ginal of each patient’s signed informed consent form.
Copies of the information leaflet and consent form
will be provided to the parents and kept in the
medical records.
Declaration of Helsinki and Good Clinical Practice
The trial will be performed in accordance with the dec-
laration of Helsinki, the conditions and principles of
Good Clinical Practice, the protocol and applicable local
regulatory requirements and laws. None of the investiga-
tors have any financial or competing interests in the trial
results.
Data protection and patient confidentiality
All investigators and trial site staff involved in this trial
must comply with the requirements of the UK Data
Protection Act 1998 and local policy (India, Bangladesh
and Sri Lanka) with regards to the collection, storage,
processing and disclosure of personal information and
will uphold the Act’s core principles. The site investiga-
tors at each site will ensure that only linked anonymised
data are received by the HELIX trial team.
Hard copies of CRFs and consent forms will be
stored inside a locked cupboard in a designated
HELIX research office at each recruiting centre, under
the supervision of the site principal investigator. Only
the HELIX research nurse, research doctor, data entry
clerk and principal investigator at each site will have
access to individual hard copies of the CRFs. Linked
anonymised electronic data will be stored in a GCP-
compliant secure UK-based server, with daily back-up.
The HELIX investigators will have access to the elec-
tronic trial data only after the data are locked for the
final analysis.
All trial staff must hold evidence of appropriate GCP
training or undergo GCP training before undertaking
any responsibilities on this trial. This training should be
updated every two years or in accordance with the
Sponsor’s policy.
Sponsorship, financial and insurance
The HELIX feasibility trial and the setup of the HELIX
trial was funded by the Bill & Melinda Gates Foundation
(OPP1069985). The main HELIX trial is funded as a part
of a Weston Garfield Chair Endowment Grant (Imperial
College London) to Dr Thayyil. The cooling devices
(Tecotherm Neo) are provided by Inspiration Health
Care, UK, on loan to the recruiting sites.
The trial is sponsored by Imperial College London.
Imperial College London will arrange insurance for neg-
ligent harm caused because of protocol design and for
non-negligent harm arising through participation in the
clinical trial.
None of the funders or sponsors have will have any
role in the study design, analysis, interpretation or publi-
cation of the results.
Monitoring, audit and inspection
The site principal investigator must make all trial
documentation and related records available for the
monitoring by the study team and by the Sponsor.
All patient data will be handled and treated
confidentially.
The study team’s monitoring frequency will be deter-
mined by an initial risk assessment performed before the
start of the trial. A detailed monitoring plan will be
generated detailing the frequency and scope of the mon-
itoring for the trial. Throughout the course of the trial,
the risk assessment will be reviewed and the monitoring
frequency adjusted as necessary.
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Protocol compliance and breaches of GCP
Prospective, planned deviations or waivers to the proto-
col are not allowed under the UK regulations on clinical
trials and must not be used. For example, it is not ac-
ceptable to enrol a participant if they do not meet one
or more eligibility criteria (for example, babies with mild
encephalopathy or no encephalopathy) or restrictions
specified in the trial protocol.
Protocol deviations, non-compliances or breaches are
departures from the approved protocol. They can
happen at any time, but are not planned. They must be
adequately documented on the relevant forms and re-
ported to the chief investigator and sponsor immedi-
ately. Deviations from the protocol which are found to
occur repeatedly will not be accepted, will require imme-
diate action and could potentially be classified as serious
breaches. Any potential/suspected serious breaches of
GCP must be reported immediately to the Sponsor with-
out any delay. The SPIRIT checklist is provided as an
Additional file 4.
Discussion
Upon completion, the HELIX trial will provide the
most comprehensive data on safety and efficacy of
cooling therapy in LMICs. Furthermore, it will
provide definitive answers into the interaction of
perinatal asphyxia and infection and how this relates
to brain injury and neuroprotection in neonatal
encephalopathy.
The HELIX trial is unique in several aspects. First, it is
a pragmatic trial conducted in the real-life scenario of
public sector tertiary neonatal units in LMICs. Cooling
therapy will be provided using existing clinical staff in
these units and research nurses (if available) will only be
involved in collection of the research data. Moreover,
HELIX uses exclusive clinical inclusion criteria and ex-
amines important clinical outcomes such as death and
disability.
The participating centres in HELIX were carefully
selected based on the following criteria: burden of en-
cephalopathy (neonatal encephalopathy admission
rate > 200 and/or delivery rate > 15,000 per year);
availability of tertiary neonatal intensive care includ-
ing cardiorespiratory support and monitoring; feasibil-
ity of long term follow-up; and adequate data quality
during the HELIX feasibility trial phase. Advanced
intensive care support such as 1:1 nursing care, inva-
sive blood pressure monitoring, nitric oxide and
extra-corporeal membrane oxygenator therapy will
not be available. Thus, the trial results would be ap-
plicable to the vast majority of public sector neonatal
units in LMIC. The participating centres have similar
guidelines for usual care of encephalopathic babies,
although some units admit only in-born babies and
others admit only out-born babies. Unlike in high-
income countries, withdrawal of life support is not
legally permitted in the participating countries.
Substantial inequality in healthcare, both in terms of
access and available resources, exists in LMICs. For ex-
ample, hospitals in the private/cooperate sector (for
profit) cater to relatively higher economic strata who
can afford to pay for their healthcare and are well
resourced. However, these hospitals have lower delivery
rates (typically 500–3000 per year) and a very low
burden from neonatal encephalopathy. In contrast,
publicly funded hospitals (not-for-profit) offer free
healthcare to patients from lower economic strata, but
are under-resourced and have heavy disease (encephal-
opathy) burden. The HELIX trial will assess the safety
and efficacy of cooling therapy in these socially and eco-
nomically disadvantaged groups of babies; hence, we will
recruit only from publicly funded hospitals (not-for-
profit) catering to a low-income population. Thus, the
HELIX trial is expected to reduce healthcare inequalities
in LMICs.
The HELIX trial results will not be generalisable to
settings that lack good neonatal care, as in sub-
Saharan Africa. If the HELIX trial demonstrates the
safety and efficacy of cooling in middle-income coun-
try settings with reasonable intensive care facilities,
the next logical step would be to conduct a large
pragmatic trial of cooling in sub-Saharan Africa and
in rural Indian states, where neonatal intensive care
facilities are not available.
Second, given the huge burden of neonatal enceph-
alopathy in LMICs, a modest benefit from cooling
therapy on a sub-group of encephalopathic infants,
might have a substantial health impact. Hence, several
additional state-of-art bacteriological, transcriptomic
and advanced neuroimaging investigations will be per-
formed as a part of the research protocol, to examine
the interactions of perinatal infection on hypothermic
neuro-protection.
We used optimised cross-platform 3 T MR se-
quences (developed at Imperial College London) so
that the data from the three different MR scanner
makes (Phillips, Siemens and GE) at the recruiting
centres can be pooled together. Before the start of re-
cruitment, we performed extensive harmonisation of
the MR scanners and compared the spectroscopy me-
tabolites on the same adult volunteer who travelled to
all recruiting different sites. Once completed, HELIX
would be the largest trial to use MR spectroscopy
biomarkers in neonatal encephalopathy.
Although, none of the advanced investigations (includ-
ing MRI) would be required in routine clinical practice
of cooling therapy, this would provide valuable insights
into the underlying disease mechanisms.
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Publications policy
Ownership of the data arising from this trial resides with
the trial team. On completion of the trial, the data will
be analysed and tabulated and a final study report pre-
pared. Consort guidelines and checklist will be reviewed
by the trial steering committee before generating any
publications for the trial to ensure they meet the
standards required for submission to high-quality peer-
reviewed journals, etc. (http://www.consort-statement.org).
Sub-studies including the HELIX trial data will be pub-
lished only after the publication of the main trial results.
A copy of the study results will be also given to the
parents of all recruited babies, if they wish. This will be
recorded at the time of recruitment and again during
follow-up. The Sponsor and funders will have no role in
the study management, analysis and interpretation of
data, writing of the report or the decision to submit the
report for publication.
Trial progress
The first patient was recruited on 16 August 2015. We
have recruited a total of 222 babies at the time of proto-
col publication (Table 2). The trial is expected to
complete recruitment by August 2018.
Additional files
Additional file 1: Screening flowchart. (PDF 196 kb)
Additional file 2: Preparation for magnetic resonance imaging. (PDF 303 kb)
Additional file 3: Magnetic resonance (3 Tesla) protocol. (PDF 821 kb)
Additional file 4: SPIRIT checklist. (PDF 77 kb)
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